UK markets closed
  • FTSE 100

    5,577.27
    -4.48 (-0.08%)
     
  • FTSE 250

    17,214.38
    +36.70 (+0.21%)
     
  • AIM

    948.60
    -0.70 (-0.07%)
     
  • GBP/EUR

    1.1115
    +0.0051 (+0.46%)
     
  • GBP/USD

    1.2951
    +0.0028 (+0.22%)
     
  • BTC-GBP

    10,437.34
    -16.31 (-0.16%)
     
  • CMC Crypto 200

    265.42
    +1.78 (+0.68%)
     
  • S&P 500

    3,269.96
    -40.15 (-1.21%)
     
  • DOW

    26,501.60
    -157.51 (-0.59%)
     
  • CRUDE OIL

    35.72
    -0.45 (-1.24%)
     
  • GOLD FUTURES

    1,878.80
    +10.80 (+0.58%)
     
  • NIKKEI 225

    22,977.13
    -354.81 (-1.52%)
     
  • HANG SENG

    24,107.42
    -479.18 (-1.95%)
     
  • DAX

    11,556.48
    -41.59 (-0.36%)
     
  • CAC 40

    4,594.24
    +24.57 (+0.54%)
     

Forte Biosciences, Inc. Announces Issuance of New U.S. Patent

·3-min read

New patent brings total U.S. patents issued to seven, covering Forte’s live biotherapeutic technology focused on inflammatory skin conditions

Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of its seventh U.S. patent (10,682,379), broadening protection to include methods for culturing gram negative bacteria from the skin. Together with the six U.S. patents previously issued, Forte now has extensive patent protection covering the composition and method of use of our technology focused on inflammatory skin conditions.

"As we continue advancing FB-401 in the clinic, we are very pleased to have our proprietary work further protected with a seventh patent issued from the USPTO," said Paul Wagner, Forte’s CEO. "FB-401, a live biotherapeutic developed together with the National Institute of Health ("NIH") and the National Institute of Allergy and Infectious Diseases ("NIAID"), represents an innovative approach to treating inflammatory skin diseases including atopic dermatitis, and we look forward to dosing our first patient in the upcoming clinical trial in mid 2020."

About Forte

Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis patients. Forte plans to advance FB-401 into a randomized Phase 2 clinical trial in mid-2020.

Forward Looking Statements

Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. Forward looking statements include statements regarding Forte’s beliefs, goals, intentions and expectations, and include statements regarding its ability to continue to advance its product candidates through the development process and achieve potential clinical development milestones in the future. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: risks related to Forte’s ability to obtain sufficient additional capital to continue to advance the company’s product candidates and preclinical programs; unexpected costs, charges or expenses; uncertainties associated with the clinical development and regulatory approval of Forte’s product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; the risk that interim results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; the risk that unforeseen adverse reactions or side effects may occur in the course of developing and testing product candidates; and risks associated with the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market.. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Source: Forte Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005192/en/

Contacts

Forte Biosciences, Inc.
Paul Wagner, CEO
investors@fortebiorx.com